BRADLEY T SUMRALL MD NPI 1679689301

NPI Details

Bradley T Sumrall, MD is a medical oncology internal medicine in Macon, GA with 23 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Bradley T Sumrall, MD NPI is 1679689301. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: MEDICAL COLLEGE OF GEORGIA SCHOOL OF MEDICINE
Graduation Year:2003

The provider's business location address is:

800 1ST ST STE 410
MACON, GA
ZIP 31201-306
Phone: (478) 743-7068
Fax: (478) 741-1354

The NPI 1679689301 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, durvalumab, 10 mg (HCPCS:J9173)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, pemetrexed, not otherwise specified, 10 mg (HCPCS:J9305)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg (HCPCS:Q5111)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Folic acid level, serum (HCPCS:82746)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Magnesium level (HCPCS:83735)
• Unclassified drugs (HCPCS:J3490)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Ct scan of chest with contrast (HCPCS:71260)
• Blood creatinine level (HCPCS:82565)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Ct scan of chest without contrast (HCPCS:71250)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Haptoglobin (serum protein) level (HCPCS:83010)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Automated urinalysis test (HCPCS:81003)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Blood test, clotting time (HCPCS:85610)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Thyroid hormone, t3 measurement, total (HCPCS:84480)
• Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic (HCPCS:G2012)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Injection, furosemide, up to 20 mg (HCPCS:J1940)
• Uric acid level, blood (HCPCS:84550)
• Ct scan of soft tissue of neck with contrast (HCPCS:70491)
• Phosphate level (HCPCS:84100)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Vitamin d-3 level (HCPCS:82306)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Ct scan of soft tissue of neck without contrast (HCPCS:70490)

The enumeration date for this NPI number is 8/23/2006 and was last updated on 9/2/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.